Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas Pharma's other long-term assets for the quarter that ended in Jun. 2026 was $2,302 Mil.
Astellas Pharma's quarterly other long-term assets
increased
from Dec. 2025 ($2,066 Mil) to Mar. 2026 ($2,197 Mil) and
increased
from Mar. 2026 ($2,197 Mil) to Jun. 2026 ($2,302 Mil).
Astellas Pharma's annual other long-term assets
increased
from Mar. 2024 ($1,392 Mil) to Mar. 2025 ($1,814 Mil) and
increased
from Mar. 2025 ($1,814 Mil) to Mar. 2026 ($2,197 Mil).
Astellas Pharma Other Long Term Assets Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Other Long Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.
What does a Other Long Term Assets of $2,302 Mil mean?
Astellas Pharma (ALPMF) has a Other Long Term Assets of $2,302 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Other Long Term Assets too high?
Astellas Pharma's current Other Long Term Assets is $2,302 Mil. Overall, Astellas Pharma has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Other Long Term Assets compare to LLY and JNJ?
Astellas Pharma's Other Long Term Assets of $2,302 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Other Long Term Assets is $2,302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.75, compared to a current price of $14.90 — trading 1% above its estimated fair value. The current Other Long Term Assets is $2,302 Mil. Astellas Pharma's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Other Long Term Assets is $2,302 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of $14.90 is trading 1% above its estimated GF Value™ of $14.75.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Other Long Term Assets: $2,302 Mil
GF Value™: $14.75 vs. price of $14.90 (1% above fair value)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
86GF Score
Get the complete analysis for ALPMF
Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
